- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00321009
LV Thrombus Pilot Study for Comparing Enoxaparin Vs. Warfarin
A Prospective Randomized Trial Comparing Enoxaparin to Warfarin for the Prevention of LV Thrombus Formation After Anterior Wall Myocardial Infarction: A 60 Patient Pilot Study
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Patients with anterior Q-wave MIs and ejection fractions<=40% will be enrolled within the first 4 days of infarction. Patients will be randomized to receive either enoxaparin 1mg/kg (maximum 100mg) subcutaneously every 12 hours for one month or heparin followed by oral warfarin for 3 months.
Clinical and safety evaluations, 2-D echocardiograms at baseline and at 3.5 months and cost analysis will be performed.
Studietype
Registrering
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Colorado
-
Denver, Colorado, Forente stater, 80262
- University of Colorado Health Sciences Center
-
-
Michigan
-
Royal Oak, Michigan, Forente stater, 48073
- William Beaumont Hospital
-
-
New York
-
Syracuse, New York, Forente stater, 13203
- St Joseph's Health Center Dept. of Cardiology
-
-
North Carolina
-
Greensboro, North Carolina, Forente stater, 27403
- LaBauer Cardiovascular Research Foundation
-
-
Pennsylvania
-
Doylestown, Pennsylvania, Forente stater, 18901
- Doylestown Hospital
-
-
Virginia
-
Virginia Beach, Virginia, Forente stater, 23454
- Cardiovascular Associates Ltd.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age 18 to 80
Anterior myocardial infarction with:
- Pathological Q-waves in at least 3 contiguous anterior precordial leads, assumed to be new
- CK peak>5 times the upper limit of normal with positive MB bands
- Ejection fraction <=40% or anterior dyskinesis or documented LV Thrombus
- MI onset < 7 days from randomization
Exclusion Criteria:
- Inability to give written informed consent
- Medical conditions that would prohibit discharge within 48 hours with the exception of need for anticoagulation
- Cardiogenic shock, rest angina unresponsive to medical therapy or serious ventricular arrhythmia in the 24 hours prior to randomization
- Patients scheduled for surgical procedure in the next 4 months that would prevent use of enoxaparin or warfarin
- Anemia: Baseline Hgb<=9 gm for women, <=10 gm for men or platelet count<100,000
- Renal insufficiency (creatinine >2.0 mg/dl)
- Serious liver disease as reflected by INR>1.3
- Stroke within past 6 months or a prior documented intracranial or subarachnoid hemorrhage
- Active bleeding or major surgery within 2 weeks prohibiting the use of anticoagulants
- Acute pericarditis
- Women of childbearing potential unless pregnancy test negative
- Cardiac or non-cardiac condition with expected survival< 6 months
- Severe peripheral vascular disease
- Patients who undergo cardiac surgery, including CABG, as a result of their index myocardial infarction
- Allergy to aspirin, heparin or warfarin, pork or pork products
- History of recurrent thromboembolic disease or a history of Protein C, Protein S, antithrombin III deficiency or known bleeding disorder.
- Current use of warfarin or need for chronic anticoagulation
- Current participation in other trials using investigational drugs or devices
- Prior enrollment in this trial
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Hva måler studien?
Primære resultatmål
Resultatmål |
|---|
|
What is the incidence of LV mural thrombus with administration of enoxaparin vs.
|
|
warfarin at 3.5 months in patients presenting with anterior wall myocardial
|
|
infarctions.
|
Sekundære resultatmål
Resultatmål |
|---|
|
What are the associated costs and length of hospital stay after randomized to
|
|
enoxaparin vs. warfarin?
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Cindy L Grines, MD, William Beaumont Hospitals
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Iskemi
- Patologiske prosesser
- Nekrose
- Myokardiskemi
- Hjertesykdommer
- Kardiovaskulære sykdommer
- Vaskulære sykdommer
- Arteriosklerose
- Arterielle okklusive sykdommer
- Embolisme og trombose
- Koronar sykdom
- Hjerteinfarkt
- Infarkt
- Koronararteriesykdom
- Trombose
- Molekylære mekanismer for farmakologisk virkning
- Fibrinolytiske midler
- Fibrinmodulerende midler
- Antikoagulanter
- Enoksaparin
Andre studie-ID-numre
- IND 59673
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .